Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13

[Image: see text] Selective degradation of the cyclin-dependent kinases 12 and 13 (CDK12/13) presents a novel therapeutic opportunity for triple-negative breast cancer (TNBC), but there is still a lack of dual CDK12/13 degraders. Here, we report the discovery of the first series of highly potent and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jianzhang, Chang, Yu, Tien, Jean Ching-Yi, Wang, Zhen, Zhou, Yang, Zhang, Pujuan, Huang, Weixue, Vo, Josh, Apel, Ingrid J., Wang, Cynthia, Zeng, Victoria Zhixuan, Cheng, Yunhui, Li, Shuqin, Wang, George Xiaoju, Chinnaiyan, Arul M., Ding, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876424/
https://www.ncbi.nlm.nih.gov/pubmed/35938508
http://dx.doi.org/10.1021/acs.jmedchem.2c00384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876424/
https://www.ncbi.nlm.nih.gov/pubmed/35938508
http://dx.doi.org/10.1021/acs.jmedchem.2c00384

Ejemplares similares